Jennifer Zlott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennifer Zlott has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Alice P. Chen
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA
14 shared publications - Alida Palmisano
Virginia Polytechnic Institute and State University
14 shared publications - Barry C. Johnson
Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland
14 shared publications - Brandon Miller
Clinical Pharmacodynamics Biomarker Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD
14 shared publications - Deborah F. Wilsker
Frederick National Laboratory for Cancer Research 1 Clinical Pharmacodynamics Biomarker Program, Applied and Developmental Research Directorate Frederick, Maryland
14 shared publications - Geraldine O'SUllivan Coyne
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
14 shared publications
Latest Publications
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Prior taxane-based therapy and duration for patients receiving the nilotinib-paclitaxel combination
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Prior taxane-based therapy and duration for patients receiving the nilotinib-paclitaxel combination
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
All adverse events at least possibly attributed to study drugs
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
All adverse events at least possibly attributed to study drugs
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Dose limiting toxicities for the nilotinib-paclitaxel combination
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Dose limiting toxicities for the nilotinib-paclitaxel combination
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Paclitaxel dose intensities during DLT evaluation
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Paclitaxel dose intensities during DLT evaluation
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Peripheral neuropathy incidence following nilotinib-paclitaxel combination therapy or paclitaxel monotherapy
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Peripheral neuropathy incidence following nilotinib-paclitaxel combination therapy or paclitaxel monotherapy
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
AUC values for paclitaxel and corresponding metabolites prior to Day 1 and after Day 8 coadministration with nilotinib
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
AUC values for paclitaxel and corresponding metabolites prior to Day 1 and after Day 8 coadministration with nilotinib
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Description of methods for DLT definition, dose modification and treatment break criteria, and pharmacodynamic analyses
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Description of methods for DLT definition, dose modification and treatment break criteria, and pharmacodynamic analyses
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Treatment histories for patients with an exceptional response to nilotinib-paclitaxel
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Treatment histories for patients with an exceptional response to nilotinib-paclitaxel
- Open Access
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Representativeness of Study Participants
- 3 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors
Representativeness of Study Participants